Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

Prioritizing Mental Health and Illness Beliefs in Psoriasis Care

Blog -Expert Insights-Bundy-Graphic

Christine Bundy, PhD, AFBPS, C Psychol
University of Cardiff
Cardiff, United Kingdom

TERMS TO KNOW

  • Comorbidities are when two or more diseases are present in a patient at the same time. With psoriasis, one common comorbidity is psoriatic arthritis, but other comorbidities can include anxiety and depression.

  • Illness beliefs are beliefs that people form over their life that impact how they view their illness and how much control they can have over it.

  • Medicine beliefs are beliefs that people form over their life that impact how they view medicine, whether it is necessary, and what concerns they may have about it.

THE 101

When it comes to psoriasis and mental health, an estimated:

  • Up to 50% of psoriasis patients suffer from depression.
  • 30% live with anxiety.
  • 10% experience thoughts of suicide.

TIMELINE OF KEY ACHIEVEMENTS

1946: Dr. Eric Wittkower begins studying the relationship between psoriasis and psychological stress.

2022: Happify Health and Almirall announce the launch of Claro — a digital platform designed to help improve mental health for those living with psoriasis in Spain, the United Kingdom, or Italy.

RECENT RESEARCH

Kleyn CE, Talbot PS, Mehta NN, Sampogna F, Bundy C, Ashcroft DM, Kimball AB, van de Kerkhof PCM, Griffiths CEM, Valenzuela F, van der Walt JM, Aberra T, Puig L. Psoriasis and Mental Health Workshop Report: Exploring the Links between Psychosocial Factors, Psoriasis, Neuroinflammation and Cardiovascular Disease Risk. Acta Derm Venereol. 2020 Jan 7;100(1):adv00020. doi: 10.2340/00015555-3375. PMID: 31742649.

Schwartz J, Evers E, Bundy C, Kimball AB. Getting under the Skin: Report from the International Psoriasis Council Workshop on the Role of Stress in Psoriasis. Frontiers in Psychology. 2016 Feb 2https://doi.org/10.3389/fpsyg.2016.00087.

As a Consultant Health Psychologist, Christine Bundy PhD, AFBPS, C Psychol knows that physical health and mental health are crucially intertwined, especially when it comes to psoriasis.

With over 40 years working to improve patient care, Professor Bundy’s research focuses on how patients’ illness and medicine beliefs can affect their mood, self-management, and disease progression.

In a recent presentation, Prof. Bundy shared the effects that mental health can have on psoriasis patients — and their health outcomes. Here, she shares what clinicians can be on the lookout for, what questions they can ask, and the topics she hopes to see uncovered in future research.

Psoriasis — More Than Just a Skin Condition

While psoriasis shows itself on the skin, it is far more than just a skin condition impacting a patient’s mental health, self-esteem, and quality of life. Prof. Bundy asks not if clinicians are measuring the right factors, but if clinicians are measuring all of the right factors — and what other factors may provide insight into a patient’s condition and predicted outcomes.

“Simply focusing on quality of life or mood is not sufficient in giving us the full-rounded picture for how we might help people to self-manage their psoriasis more effectively,” explains Prof. Bundy.

Often, clinicians will assess a patient’s:

Prof. Bundy emphasizes the need to expand this assessment to also include other factors such as a patient’s:

  • Alcohol consumption, drug use, and other forms of self-medication
  • Mood, including symptoms of anxiety and depression
  • Illness and medicine beliefs that can impact their mental health or adherence

“We know that in other long-term conditions, individual beliefs can predict outcomes for a range of long-term conditions, including diabetes functioning and management, cardiovascular disease, chronic fatigue syndrome… and stroke outcomes,” explains Prof. Bundy.

With this information, Prof. Bundy’s research emphasizes how a patient’s beliefs can impact their health outcomes — and their mental health.

How Beliefs Impact Behaviors and Mental Health

When it comes to psoriasis, Prof. Bundy shares that the extent and involvement of skin alone are not enough for clinicians to best predict a patient’s behavior, self-management, adherence, or health outcomes. Illness beliefs — or how someone views their psoriasis is a key component, and it can actually be a better predictor of outcomes than just the severity of someone’s psoriasis.

Prof. Bundy shares five core beliefs as outlined in Illness Representations and Coping with Health Threats that tend to impact clinical outcomes:

  • Symptoms: What symptoms does the patient believe or feel is part of their psoriasis?
  • Cure: Does the patient think they can be cured? What does “being cured” mean to them?
  • Control: How much control does a patient think they or their medicines have over their illness? Do they believe certain factors like weight, smoking, or alcohol use are contributing to their condition?
  • Consequences: How do they think their illness or medicine is going to affect their life, their health, their relationships, or even their employment?
  • Timeline: How long does the patient think they will need a certain treatment? Are those expectations realistic?

“If patients perceive psoriasis as a threat to their health… [or as] a threat to their identity (as a person, as a family member, as a father, as an employee), this will shape how they think about these five core beliefs and predict their emotional reactions,” says Prof. Bundy.

For example, if a patient reports symptoms that are unrelated to their psoriasis — but the patient thinks those symptoms are related — this overreporting can indicate anxiety. This behavior can provide clinicians insight into a patient’s mental health, potential comorbidities, and even their health outcomes.

What Comes Next — Centering Mental Health in Your Practice

The theme for World Psoriasis Day this year is Mental Health, but as a clinician, this is something that clinicians can prioritize in your work all year long.

The first step clinicians can take is to revisit some of the common questions you ask your patients during their visit. Prof. Bundy acknowledges that it can be difficult for clinicians to identify which people may be experiencing anxiety, depression, or be at risk for suicide due to:

  • Patients masking low mood or depression
  • Time constraints of the consultation

The second step dermatologists can make, Prof. Bundy shares, is to employ the help of your colleagues in mental health. Insist on dedicated, and preferably integrated, psychological support for your patients. Psoriasis impacts all aspects of a person’s life and coordinated care can help them achieve the best health outcomes.

Another important step is to help patients understand their behavioral choices — and how they are impacting their overall mental and physical health.

“What we have to do as clinicians — whether you’re working as a dermatologist or a health psychologist like me — is we need to switch patients’ thinking away from health-threatening features to health-protective features,” explains Prof. Bundy. This means understanding which factors may be contributing to their psoriasis, how much control they have over them, and how those behaviors may actually be a feature of their anxiety.

Lastly, Prof. Bundy encourages clinicians to expand their assessment of patients with questionnaires that address more than just skin and severity.

She points to:

With these steps and continued prioritizing of mental health, Prof. Bundy is excited for future research and what it will continue to tell us about how to support patients with psoriasis.

Categories

Recent Posts

When Cancer and Psoriasis Coexist: New IPC Guidance Puts Clarity Where It Is Needed Most

Reframing Obesity in Psoriatic Disease: From Pharmacokinetic Barrier to Therapeutic Target

Psoriasis and Metabolic Health: What IPC’s Latest Publication Means for Clinical Practice

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

When Your Patient with Psoriasis Is Diagnosed with Cancer

A patient doing well on an IL-17 inhibitor is diagnosed with cancer, and the oncologist wants the biologic stopped. It is a call most dermatologists have made without much to stand on: patients with cancer are excluded from psoriasis trials, so the entire evidence base is observational. A new IPC paper in JAAD Reviews takes a position anyway. Per the summary of product characteristics, active malignancy is not a contraindication to any biologic. IL-17 and IL-23p19 inhibitors are first-line, TNF inhibitors and deucravacitinib warrant caution, and cyclosporine is the one to avoid outright. The authors also warn that psoriasis severity is routinely underestimated once a patient is in oncology care: if they meet IPC’s criteria, they are a candidate for systemic therapy regardless of what else is on their problem list. “Too often, systemic psoriasis therapy is discontinued or never initiated in patients with cancer, even when the evidence supports safe and effective options,” says Paolo Gisondi, MD, IPC Councilor and lead author. The post includes the therapeutic options figure, designed as a reference for both specialties to work from, and a slide set for teaching and presentations.

READ NOW

Thursday, August 27, 2026

Apply Now: 2027 IPC International Fellowship Program

IPC is accepting applications for the 2027 International Fellowship Program, a 12-month opportunity for early-career dermatologists and researchers focused on psoriasis. Fellows are matched with IPC Board Members or Councilors for hands-on clinical or research experience, along with virtual mentoring, skills-development classes, and ongoing connections to IPC’s global network throughout the fellowship year. Applications are open until September 30, 2026.

APPLY NOW

Monday, August 31, 2026

IPC Generalized Pustular Psoriasis (GPP) Training Modules

Recognizing GPP in clinical practice can be a challenge, even for experienced dermatologists. IPC’s new five-part training series walks clinicians through the practical skills needed to diagnose and assess GPP with confidence: distinguishing it from plaque psoriasis and other mimicking conditions, and scoring its severity using tools such as the GPPGA and GPPASI. Each module pairs an expert-led video with a case-based exercise, and the series is built to be completed in sequence at your own pace. All five modules are free and open to everyone; watch the videos on your own or work through the assessments as you go. Score 80% or higher on each of the five assessments to earn a Certificate of Completion.

LEARN MORE

Thursday, August 13, 2026

IPC Summary Slides: Psoriasis and Metabolic Health

IPC has released a set of summary slides distilling the key findings from its recent publication on psoriasis and metabolic health, published in the Journal of the American Academy of Dermatology (JAAD). The paper outlines five priorities for improving cardiometabolic risk screening and care in patients with psoriasis. Designed for sharing, the slides give clinicians and colleagues an easy way to disseminate the findings.

LEARN MORE

Wednesday, August 5, 2026

Paradoxical Psoriasis - María Julia Cura, MD

In this Take Ten with IPC video, IPC Junior Councilor Dr. María Julia Cura discusses paradoxical psoriasis, including its definition and pathogenesis, and reviews clinical case examples, key clinical features, histopathology, predictors of disease severity, and potential treatment options.

WATCH NOW

Monday, August 3, 2026